# Internal Review — Round 1

**Role:** Internal review (Reviewer 2 mode)
**Paper:** paper.pdf
**Timestamp:** 2026-02-11T18:25:00

---

## 1. FORMAT CHECK

- **Length:** 31 pages total, main text ends on page 25 (before references/appendix). Meets 25-page requirement.
- **References:** 39 entries covering modern DiD (Callaway & Sant'Anna, Goodman-Bacon, Sun & Abraham, Rambachan & Roth), energy policy (Barbose, Fowlie, Allcott, Davis, Levinson), and welfare (EPA SCC, Novan). Adequate.
- **Prose:** All sections in paragraph form. No bullet points in main text. Introduction is flowing narrative.
- **Section depth:** Each section has 3+ substantive paragraphs. Robustness has 3 focused subsections.
- **Figures:** 9 figures (8 main + 1 appendix), all with proper axes, labels, and confidence bands.
- **Tables:** 6 tables with real numbers, standard errors, and notes.

## 2. STATISTICAL METHODOLOGY

- **Standard errors:** Reported for all coefficients in all tables. PASS.
- **Significance testing:** p-values and stars reported. PASS.
- **Confidence intervals:** 95% CIs in Table 3 and event study figures. PASS.
- **Sample sizes:** N=1,479 reported. 28 treated, 23 never-treated. PASS.
- **DiD with staggered adoption:** Uses Callaway & Sant'Anna with never-treated controls. TWFE shown as benchmark only. Sun-Abraham and SDID as robustness. PASS.

## 3. IDENTIFICATION STRATEGY

Credible. Parallel trends supported by event study with flat pre-trends. Honest DiD sensitivity appropriately acknowledges fragility at long horizons. Multiple robustness checks (alternative estimators, control groups, weather, concurrent policies, COVID exclusion).

Remaining concern: Industrial placebo shows -19.3% decline (not null), which complicates falsification. Paper now discusses this honestly as potential deindustrialization confounder.

## 4. LITERATURE

Well-positioned. Added Metcalf & Hassett (1999), Mildenberger et al. (2022), and Abadie et al. (2010) per v5 reviewer requests.

## 5. WRITING QUALITY

Substantially improved from v5. Shleifer-style narrative introduction, no enumerated lists, active voice throughout. Prose review identified minor improvements (opening sentence, data section codes) which have been addressed.

## 6. OVERALL ASSESSMENT

**Strengths:** Modern heterogeneity-robust methods, transparent reporting of fragility, Shleifer-quality prose, important policy question, novel population-level evidence.

**Weaknesses:** Industrial placebo not null; long-run estimates fragile to parallel trends violations; wild cluster bootstrap only applied to TWFE.

DECISION: MINOR REVISION
